AmMax Bio and MD Anderson Announce Agreements to Advance Development of AMB-066 in Colorectal Cancer Patients with Minimal Residual Disease AmMax Bio and MD Anderson to Advance Development of AMB-066 in Colorectal Cancer Patients with Minimal Residual Disease

AmMax Bio to Present at the Oppenheimer Healthcare Private Company Showcase REDWOOD CITY, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- AmMax Bio, Inc., a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, today announced that it...